SS-31 (Elamipretide)

Summary

SS-31 — developed as elamipretide and now sold as the approved drug Forzinity — is a small peptide with an unusual trick: it accumulates inside mitochondria, the cell's energy factories, where it binds a membrane lipid called cardiolipin and helps stabilize the machinery that produces energy. That makes it one of the most scientifically serious "mitochondrial" compounds, and in 2025 it crossed a real line: the FDA approved it (as Forzinity) for Barth syndrome, an ultra-rare genetic mitochondrial disease — its first and so far only approval. But the rest of its clinical record is sobering: its large Phase 3 trial in primary mitochondrial myopathy missed its goals, and its development in other conditions has mostly disappointed. So SS-31 is simultaneously a genuine, newly approved drug for one rare disease and a compound whose broad "anti-aging / mitochondrial repair" reputation is built on laboratory promise that human trials have repeatedly failed to confirm.

What people use it for

The approved use is narrow and specific: treating Barth syndrome in patients of at least 30 kg. Everything else is off-label or gray-market. In longevity and biohacking circles, "SS-31" is used by healthy people for anti-aging, cellular energy, exercise capacity, and "mitochondrial repair," on the logic that a compound which protects mitochondrial function should slow age-related decline. It is also discussed in the context of conditions where it was studied but not approved — mitochondrial myopathy, heart failure, kidney injury, and dry age-related macular degeneration. The evidence sections separate the one place SS-31 is proven enough to be approved from the many places it has been tried and the places it has only been hyped.

Human evidence

SS-31/elamipretide has an unusually large and instructive human trial record — and it tells a two-sided story.

Barth syndrome (the approved use). In Barth syndrome — an ultra-rare, life-limiting genetic disorder affecting the heart and skeletal muscle — elamipretide showed benefit in skeletal muscle strength and cardiac measures (in the TAZPOWER crossover trial and its long open-label extension), which supported the FDA's accelerated approval in September 2025, making it the first treatment for the condition. Two honest qualifiers matter: this is an ultra-rare disease studied in very small numbers (Barth syndrome affects only around 150 people in the US), and it is an accelerated approval, meaning continued approval may depend on confirmatory trials. The evidence was strong enough to approve, but it is not the large-population, fully-confirmed picture behind a mass-market drug — which is why this brief grades the Barth claim S rather than S+.

Primary mitochondrial myopathy (the big failure). The most important cautionary result is MMPOWER-3 (Karaa et al., Neurology, 2023): a Phase 3 randomized, double-blind, placebo-controlled trial of elamipretide (40 mg/day subcutaneously for 24 weeks) in adults with primary mitochondrial myopathy. It did not meet its primary endpoints (a six-minute walk test and a fatigue measure). A later post hoc analysis suggested possible benefit in specific genetic subgroups, which is hypothesis-generating but not proof — post hoc subgroup findings need their own prospective trials. The headline remains: a large, well-designed Phase 3 trial in mitochondrial disease was negative, which is exactly why the broad "restores cellular energy in mitochondrial disease" claim grades C.

Other conditions. Beyond Barth, elamipretide's development in more common conditions — including heart failure and dry age-related macular degeneration — has been largely unsuccessful at meeting primary endpoints. The overall human pattern is a compound that works in one narrow approved setting and has repeatedly failed to show benefit elsewhere.

Animal / preclinical evidence

The preclinical case is genuinely strong — and is the source of all the excitement (and the over-promising). SS-31 is a cell-permeable, positively charged tetrapeptide that concentrates several-thousand-fold inside mitochondria and binds cardiolipin, a lipid unique to the inner mitochondrial membrane that organizes the proteins of the electron transport chain. By stabilizing cardiolipin and the cristae structure, SS-31 helps preserve efficient energy (ATP) production and reduces the leak of damaging reactive oxygen species. In a wide range of animal and cell models — aging muscle and heart, ischemia-reperfusion injury, kidney injury, neurodegeneration — it has shown protective effects on mitochondrial function. This is a deep, well-characterized mechanism, and it is why SS-31 has been taken seriously enough to run many human trials. But the lesson of those trials is precisely that a compelling mitochondrial mechanism in animals has not reliably translated into clinical benefit in humans outside the one approved rare disease — the central reason the anti-aging claims grade conservatively.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Among longevity users, "SS-31" is reported to improve energy, stamina, exercise recovery, and a general sense of vitality, sometimes alongside other "mitochondrial" or NAD-related compounds. These reports are uncontrolled, heavily subject to placebo and expectancy effects, and — importantly — describe a use (anti-aging in healthy people) that has no human trial support at all; the product is also gray-market "SS-31" of unverified identity and purity rather than the approved drug. They carry very low evidentiary weight against a clinical record in which large trials in actual disease mostly failed.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

The clearest published human dosing is from the MMPOWER-3 trial, which used 40 mg once daily by subcutaneous injection for 24 weeks — and it is worth stating plainly that this trial did not meet its primary endpoints, so the figure is study context, not evidence of benefit. Elamipretide as the approved Barth-syndrome drug (Forzinity) is a prescription medicine whose dosing is determined and supervised by a clinician for that specific condition. None of these figures are a protocol for healthy people, and they do not transfer to gray-market "SS-31" of unknown concentration. As always: context only, never a recommendation.

Safety & side effects

Across its many trials, elamipretide's most consistent side effect has been injection-site reactions (it is given subcutaneously), and in the controlled studies it was otherwise reasonably tolerated — part of why it could be approved for Barth syndrome and advanced through multiple Phase 3 programs. Because it is a newly and narrowly approved drug, its fullest characterized safety profile applies to the Barth-syndrome population under medical supervision; long-term safety in healthy people taking gray-market "SS-31" for anti-aging is entirely uncharacterized, because no such studies exist. The approved product is a prescription medicine with monitoring; the "research only" peptide sold online is unapproved material of unverified identity, purity, and dose, carrying the usual contamination and mislabeling risks on top of an unstudied use. "Tolerated in disease trials" is not the same as "established safe for indefinite use in healthy adults."

Regulatory / legal status

SS-31/elamipretide's status changed meaningfully in 2025. As Forzinity (elamipretide HCl), it received FDA accelerated approval on September 19, 2025 for Barth syndrome in adult and pediatric patients weighing at least 30 kg — the first approved therapy for that ultra-rare mitochondrial disease. Because it is an accelerated approval (a pathway for serious conditions with unmet need), continued approval may be contingent on confirmatory trials.

Two boundaries define everything else. First, the approval is only for Barth syndrome: elamipretide is not approved for mitochondrial myopathy (where its Phase 3 trial failed), heart failure, macular degeneration, "mitochondrial health," or anti-aging, and those uses were not authorized. Second, the "SS-31" sold online for energy and longevity is not the approved drug — it is gray-market, "research only" material, unapproved and unregulated, used for purposes that have never been tested in humans. Regulatory and legal status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

SS-31 is a darling of longevity and "mitochondrial health" content, often presented as a cutting-edge compound that "repairs your mitochondria" and fights aging — and the 2025 FDA approval is now used to lend it credibility. The accurate version is more disciplined and more interesting: SS-31 has a real, deeply studied mitochondrial mechanism and is now a legitimately approved drug — but only for one ultra-rare genetic disease (Barth syndrome), via an accelerated pathway in tiny patient numbers. The crucial omission in the hype is its track record of failure in larger human trials: its Phase 3 study in mitochondrial myopathy missed its endpoints, and other indications largely failed too — so "FDA-approved" is true but does not mean "proven for energy or anti-aging." And the product longevity users actually buy is gray-market "SS-31," not the approved medicine, used for a purpose with zero human evidence. Where coverage distinguishes the narrow approval and strong mechanism from the broad, unproven anti-aging claims, it squares with the record; where it implies an approved anti-aging "mitochondrial repair" drug, it badly overstates the evidence. The critique is of the framing, not of a legitimately approved medicine.